Summary
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript
Scynexis, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| WL William Liberti Wealth Effects LLC | 10,937.5 | $2.08M | $52,390.62 | -$2.03M | -97.48% |
 Michael Byun SageView Advisory Group LLC | 4.87 | $197.34 | $23.38 | -$173.96 | -88.15% |
 Amy Taylor Pingora Partners LLC | 1,500 | $91,440 | $6,900 | -$84,540 | -92.45% |
Scynexis, Inc. (SCYX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Scynexis, Inc. ever had a stock split?
Scynexis, Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | David Angulo CEO | NASDAQ (NMS) Exchange | 811292309 CUSIP |
| US Country | 18 Employees | 17 Jul 2020 Last Dividend | 1 Jun 2026 Last Split | 2 May 2014 IPO Date |
Overview
SCYNEXIS, Inc. is a biotechnology firm focused on the development of novel treatments for fungal infections. Based in the United States, more specifically in Jersey City, New Jersey, the company has established itself as a significant player in the industry since its inception in 1999. Originally founded as SCYNEXIS Chemistry & Automation, Inc., it underwent a name change to SCYNEXIS, Inc. in June 2002, marking a pivotal moment in its history towards a more focused biotechnological mission. SCYNEXIS, Inc. boasts a robust portfolio of collaborations with leading pharmaceutical companies such as Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC. These partnerships underscore its commitment to advancing its drug development programs, particularly for its lead candidate, ibrexafungerp, and securing its commercialization rights across various global markets.
Products and Services
BREXAFEMME: A groundbreaking product by SCYNEXIS, BREXAFEMME is approved for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection, as well as recurrent VVC. It represents a significant advancement in the management of these common yet often distressing conditions, offering patients a new treatment option.
Ibrexafungerp: Leading the company's product pipeline, Ibrexafungerp is an innovative intravenous drug designed to combat a broad spectrum of fungal infections. Its potential applications are wide-ranging and include the treatment of invasive candidiasis, refractory invasive fungal infections, and invasive aspergillosis, in addition to VVC and recurrent VVC. The development of Ibrexafungerp underscores SCYNEXIS's commitment to addressing unmet medical needs in the area of antifungal treatments through cutting-edge research and development.
